Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics, Inc. received a Schedule 13G showing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 905,798 shares of Avalo common stock, representing 4.9% of the class.
The filing notes that the reporting persons exceeded 5% beneficial ownership of Avalo’s common stock on January 28, 2026, but had reduced their holdings to 4.9% by the date of the statement. Voting and investment power over these shares is reported as shared, with no sole voting or dispositive power.
The Vanguard Group filed an amended Schedule 13G reporting passive ownership in Avalo Therapeutics Inc common stock.
Vanguard reports beneficial ownership of 804,084 shares, representing 4.43% of Avalo’s common stock as of the event date. It has no sole voting or dispositive power, with shared voting power over 92,039 shares and shared dispositive power over 804,084 shares.
The filing states the holdings are in the ordinary course of business and not for changing or influencing control. Vanguard notes a January 12, 2026 internal realignment, after which certain subsidiaries are expected to report ownership separately while continuing the same investment strategies.
Affinity Asset Advisors, LLC and Michael Cho reported beneficial ownership in Avalo Therapeutics, Inc. common stock totaling 1,051,054 shares, or about 5.7% of the company. The shares are held through Affinity Healthcare Fund, LP, with Affinity acting as investment manager and exercising voting and investment power.
The ownership percentage is based on 18,512,757 Avalo shares outstanding as of December 31, 2025, as disclosed in Avalo’s Form S-3 filed on January 8, 2026. The reporting persons state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Avalo.
Avalo Therapeutics, Inc. reported that it estimates having approximately $98 million in cash, cash equivalents and short-term investments as of December 31, 2025, based on figures shared in an updated investor presentation.
The company emphasized that this cash estimate is unaudited, preliminary and does not include full details of its financial condition or results for the year, which will be provided in its future annual report. Avalo also made the updated investor presentation available on its website and attached it as an exhibit to this report for use in meetings with investors.
Avalo Therapeutics, Inc. has filed a shelf registration statement that allows it to offer up to $750,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. The filing also carries forward $326,585,963 of previously registered but unsold securities from an expiring shelf under SEC Rule 415(a)(6), so those amounts remain available without interruption. Proceeds from future offerings may be used for general corporate purposes, including clinical trials, research and development, and general and administrative expenses. Avalo is a clinical-stage biotechnology company focused on IL‑1β-based therapies, led by AVTX‑009 in a Phase 2 trial for hidradenitis suppurativa, with topline data expected in the second quarter of 2026.
Avalo Therapeutics, Inc. reported an insider Form 4 transaction by its Chief Medical Officer. On December 10, 2025, the officer disposed of 1,013 shares of Avalo Therapeutics common stock at $4.1 per share. After this transaction, the officer beneficially owns 3,622 shares, which include shares acquired pursuant to Avalo Therapeutics' Employee Stock Purchase Plan as part of this reporting transaction.
Avalo Therapeutics’ chief strategy officer reported a small change in personal share holdings. On 12/10/2025, the officer disposed of 637 shares of Avalo Therapeutics common stock at a price of $4.1 per share, according to an SEC insider ownership report.
After this transaction, the officer directly beneficially owns 2,655 shares of Avalo Therapeutics. These 2,655 shares are described as having been acquired under the company’s Employee Stock Purchase Plan as part of the reported activity, indicating ongoing participation in the company’s equity programs.
Avalo Therapeutics, Inc. reported an equity transaction by its Chief Legal Officer on December 10, 2025. The officer reported a transaction in Avalo common stock coded “F” involving 1,016 shares at a price of $4.10 per share. After this transaction, the officer beneficially owns 3,634 shares of Avalo common stock. A note explains that these 3,634 shares were acquired under Avalo’s Employee Stock Purchase Plan as part of the reported transaction.
Avalo Therapeutics, Inc. chief financial officer Christopher Sullivan reported a change in his ownership of Avalo common stock. On 12/10/2025, 155 shares of common stock were disposed of at $4.1 per share, leaving him with beneficial ownership of 17,338 shares.
The beneficially owned amount includes 417 additional shares acquired pursuant to Avalo Therapeutics, Inc.'s Employee Stock Purchase Plan as a part of this reporting transaction. The report is a Form 4 filed by one reporting person in his capacity as an officer (chief financial officer).